

Proventa's recent survey of clinical trial suply chain leaders highlights Cold Chain & Temperature Management as a top investment priority. Key industry challenges primarily include Drug Storage & Distribution, Trial Rescue, and Packaging and Labelling. Understanding these trends is crucial for steering stakeholder decisions and effectively navigating the evolving Clinical Operations landscape.



Top Investment Areas for 2024-2025

Our latest Clinical Trial Supply Chain Strategy Meeting pinpointed top investment trends. Cold Chain and Temperature Management led with 13%, emphasizing its essential role in maintaining product integrity. Close behind were Drug Storage & Distribution and Trial Rescue, highlighting a focus on supply chain efficiency and flexible strategies, each attracting around 10% interest. Notable too, emerging technologies like Artificial Intelligence and Machine Learning are now capturing 5% of investments, signaling a shift towards data-driven operations. Other areas such as Consulting, Site Selection, and Patient Recruitment are also key focuses underscoring a well-rounded investment approach in clinical development.



Top 10 Challenges 2024: What Peers are Focusing on



Vendor Selection and Oversight



Return and Destruction of Trial Materials



Acquisition, Storage, and Distribution Logistics Optimization



Risk Management in Drug Supply



Comparator Drug
Procurement



Cost Optimization and Negotiation with Vendors



Supply Chain Forecasting and Demand Planning



Technology Transfer and Product Scale-Up



Labeling and Packaging Compliance




Supply Chain Data Analytics and Reporting




Key Investing Insights from Attendees

This section summarizes key insights from our recent strategy meetings, providing valuable information for solutions providers in the drug discovery space seeking qualified leads and RFP opportunities. You can connect with qualified leads and position your products and services to address their specific needs.







Don't miss out on prime RFP-ready opportunties! Almost **80% of companies** are actively evaluating solutions, presenting prime opportunities for engagement through roundtable discussions and targeted 1-on-1 meetings. Secure leads at every stage with Proventa's Strategy Meetings.


O-3 months 16% 3-6 months 26% 6-12 months 58% of companies plan to invest within 6-12 months, 42% in the next 6 months! Don't miss out - engage with these decision makers at the upcoming strategy meetings. We connect you with companies primed for investing in solutions!





Delegate Breakdown: Attendee Profile at Proventa's 2023 Strategy Meetings






Main Therapeutic Areas

Oncology leads the charge with 27% of attendees focused on this critical field. Immunocology (12%) and Rare Diseases (11%) research also hold strong interest, followed by Neurology (11%) and Cardiovascular (9%). This diverse group offers a wealth of potential partnerships across a broad spectrum of therapeutic areas.

Explore the full landscape of therapeutic areas driving clinical operations.





Our Valued Past Sponsors



acolad.





























































































































Discover what past event partners and attendees are saying about the impact and value of our strategy meetings



CLICK HERE TO WATCH A VIDEO OF OUR **R&D Strategy Meeting**



CLICK HERE TO WATCH A VIDEO OF OUR Manufacturing **Strategy Meeting**



CLICK HERE TO WATCH A VIDEO OF OUR **Clinical Trials Strategy Meeting**

Fresh Life Science Insights











